Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;13(5):1110-1122.e1.
doi: 10.1016/j.jaip.2025.01.010. Epub 2025 Jan 16.

Mucus Plug Score Predicts Clinical and Pulmonary Function Response to Biologic Therapy in Patients With Severe Asthma

Jeremias Götschke  1 , Julia Walter  1 , Gabriele Leuschner  1 , Michael Gerckens  2 , Melanie Götschke  1 , Pontus Mertsch  1 , Carlo Mümmler  2 , Alexandra Lenoir  1 , Michaela Barnikel  1 , Julien Dinkel  3 , Jürgen Behr  1 , Nikolaus Kneidinger  4 , Judith Eva Spiro  3 , Katrin Milger  5
Affiliations
Free article

Mucus Plug Score Predicts Clinical and Pulmonary Function Response to Biologic Therapy in Patients With Severe Asthma

Jeremias Götschke et al. J Allergy Clin Immunol Pract. 2025 May.
Free article

Abstract

Background: Mucus plugging has been identified as an important feature of severe asthma contributing to airway obstruction and disease severity. Recently, improvement in mucus plugging has been found on treatment with several biologic therapies.

Objectives: To analyze associations of baseline characteristic with the mucus plugging score (MPS) and to determine whether the MPS at baseline predicts the clinical and functional response to biologic treatment in patients with severe asthma.

Methods: We retrospectively analyzed biologic-naive patients with a suitable computed tomography scan available at baseline. We calculated the MPS and analyzed correlations with baseline parameters and improvements in biomarkers, pulmonary function, and clinical parameters after 4 months of biologic therapy.

Results: We included 113 patients in the baseline cohort, 101 patients of whom had sufficient data after 4 months of biologic therapy for the follow-up analysis. Computed tomography showed mucus plugging in 77% of patients (median MPS, 4). Multivariate regression analysis showed a correlation of MPS with lower FEV1 (ρ = -0.24; P = .009) and diffusing capacity for carbon monoxide (ρ = -0.26; P = .01), and higher FeNO (ρ = .36; P = .0003) at baseline. Patients received treatment with anti-IgE (8.8%), anti-IL-5 (27.4%), anti-IL-5R (37.2%), anti-IL-4R (25.7%), and anti-thymic stromal lymphopoietin (0.9%) in clinical routine. Baseline MPS correlated with improvements in FEV1 (β = 0.72; P = .01) and Asthma Control Test (β = 0.24; P = .001) in multivariate regression analysis.

Conclusion: Our study suggests that a higher MPS correlates with worse pulmonary function at baseline but also predicts a larger clinical and pulmonary function response to biologic therapies in severe asthma.

Keywords: Antibody; Asthma; Biologic therapy; Diffusion capacity; FEV(1); FeNO; Mucus plug score; Mucus plugging; Pulmonary function; Response.

PubMed Disclaimer